Cure GM1 Invests $400,000 to Advance Development of Enzyme Replacement Therapy
Cure GM1 is dedicated to investing in research, seeding new projects, and to the development…
2024 Cure GM1 Impact Report
Our summary of impact in 2024 is now available to read. Although this year was hard with…
Sanofi Press Release: AMETHIST Trial Discontinued
We regret to inform you that in Sanofi’s quarterly press release issued today that the…
2023 Cure GM1 Impact Report – Annual Update And Beyond
Our summary of impact in 2023 is now available to read. After some time reflecting, everyone…
Cure GM1 to Collaborate with xCURES for Natural History Study Pilot
Cure GM1, a 501(c)(3) nonprofit organization located in Albany, CA, USA is proud to announce…
Over $461K Grant toward Enzyme Replacement Therapy with TEGA Therapeutics
TEGA Therapeutics, Inc. has been awarded a Phase I Small Business and Innovative Research (SBIR)…
Gelb Laboratory Publishes Third GM1 Newborn Screening Paper
Cure GM1 provided seed funding for, and families from the GM1 community provided dried blood…
2022 Cure GM1 Impact Report – Impact in 2022 and Beyond
Our summary of impact in 2022 is now available to read. After some time reflecting,…
The Voice of the Patient Report from the GM1 Gangliosidosis Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD)
You can now download and read the touching and impactful summary of input from GM1…
About the GM1 Gangliosidosis Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting with FDA
The GM1 Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD) was held on Friday, October 14 as…